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enotypes Associated With Myocardial
nfarction Risk Are More Common in
frican Americans Than in European Americans
avid E. Lanfear, MD,* Sharon Marsh, PHD,* Sharon Cresci, MD,* William D. Shannon, PHD,*
ohn A. Spertus, MD, FACC,† Howard L. McLeod, PHARMD*
t. Louis and Kansas City, Missouri
OBJECTIVES This study was designed to describe the frequencies of multiple myocardial infarction (MI)
risk-associated genotypes among different racial groups.
BACKGROUND Racial disparities in the prevalence of cardiovascular disease (CVD) are well known. Recent large
Japanese case-control studies identified connexin-37 (GJA-4), plasminogen activator inhibitor-1
(PAI-1), and stromelysin-1 (MMP-3) polymorphisms as risk factors for MI, but the prevalence
of these genotypes among different racial groups in the U.S. needs to be determined.
METHODS Genomic deoxyribonucleic acid from 95 healthy African Americans (AA) and 95 healthy
European Americans (EA) was used for genotyping. Deoxyribonucleic acid containing the
region of interest was amplified using the polymerase chain reaction, followed by genotyping
using pyrosequencing.
RESULTS All three MI-risk genotypes were observed in both populations and were in Hardy-Weinberg
equilibrium. The frequencies of two of the three “risk-associated” genotypes were significantly
higher in the AA population: GJA4 C1019T T/T: AA, 20%, EA, 7% (p  0.053); MMP3
1171delA A/A: AA, 78%, EA, 24% (p  0.001); PAI-1 668delG G/G: AA, 55%, EA,
16% (p  0.001). The likelihood of two or more high-risk genotypes was 3.3% among EA
subjects and 51% in the AA group (p  0.001). We found that 9.1% of AA had all three
high-risk genotypes, compared with 0% among the EA group (p  0.0097).
CONCLUSIONS We found higher frequencies of disease-associated genotypes in AA than in EA. Our results
also show that more AA than EA carry multiple risk-associated genotypes. Future studies
need to assess whether such genetic profiles predict adverse outcomes in U.S. populations and
contribute to racial disparities in CVD burden. (J Am Coll Cardiol 2004;44:165–7) © 2004
by the American College of Cardiology Foundatione
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ofrican Americans (AA) appear to be disproportionately
ffected by cardiovascular disease (CVD) compared with
uropean Americans (EA). The prevalence of CVD among
A men and women is nearly 40% compared to 23% to 30%
or EA (1). Further, the rates of incident myocardial
nfarction (MI), death due to coronary heart disease
CHD), and heart failure are all higher in AA than EA
1,2). The understanding and eradication of such disparities
as become a national priority (3) and is a primary goal of
he Department of Health and Human Services’ Healthy
eople 2010 agenda (4).
Although the presence of such differences is clear, the
nderlying reasons are not completely understood. Certainly
ifferences in access to health care and socioeconomic status,
s well as differences in the processes of medical care, may
xplain potential disparities in outcome (5). However, the
xtent to which genetic variation may contribute to the
From the *Washington University School of Medicine, Departments of Medicine,
enetics, Molecular Biology, and Pharmacology, and Division of Biostatistics, St.
ouis, Missouri; and the †Mid America Heart Institute-University of Missouri
ansas City, Kansas City, Missouri. This work was supported in part by the NIH
harmacogenetics Research Network (U01 GM63340) and the data have been
ubmitted to PharmGKB.org.
Manuscript received December 15, 2003; revised manuscript received March 5,
w004, accepted March 23, 2004.xcess CVD burden on AA remains relatively unexplored.
ecent advances in cardiovascular genetics have highlighted
nteractions between common genetic variants and CVD
6), making possible the exploration of the role of these
enetic variations in racial health disparities.
A recent landmark article by Yamada et al. (7) explored
12 polymorphisms in 71 candidate genes and their rela-
ionship to the risk of having an MI. After screening 909
apanese subjects, researchers validated the results in an
dditional 4,152 subjects. Three single-nucleotide polymor-
hisms (SNP) in three candidate genes were identified that
howed significant correlations to incident MI: connexin-37
HUGO name GJA-4), C1019T (T allele) in men, and
tromelysin-1 (MMP-3) 1171delA (insertion allele) and
lasminogen activator inhibitor-1 (PAI-1) 668delG (in-
ertion allele) in women. An even more recent study from
he same group included 1,661 Japanese subjects and con-
rmed a significant correlation of the MMP-3 and GJA-4
olymorphisms to the presence of CHD (8).
The functional significance of these variants has been
xplored. Both the MMP-3 and PAI-1 polymorphisms are
n the promoter regions of the respective genes, and previ-
us investigators have shown allele-specific interactions
ith nuclear proteins, and altered transcription levels in
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Racial Differences in MI-Associated Genotypes July 7, 2004:165–7itro (9,10). Mechanistic studies of the GJA-4 polymor-
hism are still needed; at present this polymorphism has
een correlated to the presence of carotid atherosclerosis
11).
Both of these large case-control studies were performed
n Japanese subjects, and there is little information about the
requency of these polymorphisms in AA or EA subjects. As
first step toward a large disease-association study, the
requencies of these three variants were assessed as both
ndividual SNPs and in aggregate in healthy population
amples of AA and EA subjects.
ETHODS
ubjects. After written informed consent and human stud-
es committee approval, genomic deoxyribonucleic acid
DNA) was extracted from whole blood of 95 EA and 95
A healthy volunteers. The DNA was resuspended in 10
M Tris/1 mM EDTA pH 8 and used directly for
olymerase chain reaction (PCR) analysis.
enotyping. The DNA segments containing the region of
nterest were amplified with PCR. Polymerase chain reac-
ion primers were designed using Primer Express version 1.5
ABI, Foster City, California), and the pyrosequencing
rimers were designed using the Pyrosequencing SNP
rimer Design Version 1.01 software (Pyrosequencing,
ppsala, Sweden). The PCR primers and conditions are
isted in Table 1. Polymerase chain reaction was carried out
sing Amplitaq Gold PCR master mix (ABI, Foster City,
alifornia), 5 pmole of each primer (IDT, Coralville, Iowa),
Abbreviations and Acronyms
AA  African Americans
CHD  coronary heart disease
CVD  cardiovascular disease
DNA  deoxyribonucleic acid
EA  European Americans
GJA-4  connexin-37
MI  myocardial infarction
MMP-3  stromelysin-1
PAI-1  plasminogen activator inhibitor-1
PCR  polymerase chain reaction
SNP  single nucleotide polymorphism
Table 1. Polymerase Chain Reaction and Pyro
Polymorphism Prime
GJA-4 C1019T Forward 5-biotin-AACCTG
Reverse 5-CATCCCAGGC
Internal 5-GGGACGACT
MMP-3 –1171delA Forward 5-biotin-CACGG
Reverse 5-CTGCCACCAC
Internal 5-ACAAGACATG
PAI-1 –668delG Forward 5-GGGGCACAG
Reverse 5-biotin-TCCCTC
Internal 5-TGGACACGTGJA-4  connexin-37; MMP-3  stromelysin-1; PAI-1  plasmnd 1 ng DNA. Pyrosequencing was carried out as previ-
usly described (12) using the Pyrosequencing PSQ hs96A
nstrument and software.
tatistics. The frequency of homozygosity for the risk-
ssociated allele or the composite genotype was compared
etween AA versus EA subjects using Fisher exact test. All
values were adjusted for multiple comparisons using
ermutation testing, as previously described (13).
ESULTS
ur results for allele frequency of PAI-1 C1019T and
MP-3 1171delA in both populations and GJA4
668delG in EA were consistent with those of other investi-
ators (11,14,15). The risk-associated genotypes for MMP-3
nd PAI-1 are more common in AA than EA subjects (Table
) (p  0.001 for each). Even more striking is the number of
ubjects with more than one high-risk genotype (Fig. 1).
mong AA subjects 51.1% were homozygous for at least two
igh-risk alleles, compared with only 3.3% in the EA group (p
0.001). No EA subjects were homozygous for all three
igh-risk alleles; however, eight AA subjects (9.1%) did fulfill
his criterion (p  0.0097).
ISCUSSION
frican Americans are at higher risk of CVD, including CHD
nd MI (1). The extent to which this excess burden is
ccounted for by genetic determinants remains unknown.
ncing Primers and Conditions
uence
Annealing Temp.
(C°)
ACAGAGGAGAGGC-3 62°
CAGACT-3
GG-3
CTGGCCTAAAG-3 55°
GTTCTCCTT-3
TTTT-3
GAGTCTGGA-3 60°
CCTGCCATGT-3
G-3
igure 1. Frequency (%) of compound risk-associated genotypes in
frican-American (AA) and European-American (EA) subjects with
omplete genotype information (n  91 for EA, n  88 for AA). GJA4 
onnexin-37; MMP3  stromelysin-1; PAI-1  plasminogen activator
nhibitor-1.seque
r Seq
ACC
AGC
TGG
CAC
TCT
GT
AGA
ATC
GGGinogen activator inhibitor-1.
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July 7, 2004:165–7 Racial Differences in MI-Associated Genotypesith the identification and validation of common genetic
ariants that carry an elevated risk of MI, there is now the
otential to explore this question. Our results, showing mark-
dly higher frequencies of both single and compound risk-
ssociated genotypes in AA than in EA subjects, suggest a
otential genetic contribution to the observed racial differences
n CHD risk. However, this should be interpreted with caution
ecause the frequency of these genotypes in AA is greater than
he observed incidence of CHD and MI in this population.
his raises the question of whether these risk-associated
enotypes carry the same significance in AA as has been shown
n Japanese subjects. A differential impact of these polymor-
hisms, if present, could suggest either that they are in linkage
ith a causative variant or that their influence requires other
enetic modifiers that may differ between races. This impor-
ant question can now be asked in studies in AA and EA with
HD or MI.
Though this is a small study (190 total subjects), our
ndings are significant for several reasons. First, they
escribe the genetic landscape for patients likely to be
ncountered in U.S. populations and can be used to derive
ample size for future studies. Second, we have extended
revious observations to note the frequency of multiple
enetic risk factors in the same individuals. This is pertinent
ecause even though the risks associated with these geno-
ypes are very significant by statistical standards, individually
hey were of somewhat modest clinical magnitude. On the
ther hand, if genotypes at several relevant loci were known,
t might be possible to more accurately identify individuals
t significantly higher CVD risk who could benefit from a
ore aggressive early strategy to prevent adverse outcomes.
hus, the fact that a substantial proportion of both AA and
A populations can be identified with multiple risk-
ssociated alleles is intriguing for the alleles’ potential utility
n future health screening. Such data are needed to design
nd carry out larger, more definitive studies to assess the
umulative risk of MI in patients with these compound
enotypes, as well as their prognostic importance for those
ith established disease. Finally, these data emphasize the
otential opportunity to assess the relevance of common
enetic variants to the differences in CVD among various
acial groups, while giving an intriguing hypothesis from
able 2. Genotype Frequency (%) Among 95 African Americans
Polymorphism GJA-4 C10119T*
enotype C/C C/T T/T 
frican American 25.3 54.9 19.8
uropean American 48.4 44.1 7.5
apanese‡ 71.7 25.4 2.9
p  0.053; †p  0.001. Comparisons for homozygous high-risk allele in African A
n reference 7.
Abbreviations as in Table 1.hich to start this vital endeavor.eprint requests and correspondence: Dr. Howard L. McLeod,
ashington University School of Medicine, 660 South Euclid
venue, Campus Box 8069, St. Louis, Missouri 63110-1093.
-mail: hmcleod@im.wustl.edu.
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